Since FDA approval in July 2009, use of prasugrel has steadily increased among patients with ACS undergoing PCI. However, use of this drug in patients with known contraindications is not uncommon, ...
PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended ...
July 9, 2012 (Patras, Greece) — The first direct pharmacodynamic comparison of two new antiplatelet agents, prasugrel (Effient, Lilly/Daiichi-Sanyo) and ticagrelor (Brilinta/Brilique, AstraZeneca), ...
WASHINGTON, DC — A real-world comparison of clopidogrel vs prasugrel (Effient, Lilly/Daiichi-Sankyo) in nearly 12 000 acute coronary syndrome (ACS) patients undergoing PCI revealed no significant ...
For STEMI patients undergoing primary PCI, there are no significant differences in the risks of death, MI, or stroke between those treated with prasugrel and those who received ticagrelor, nor are ...
SAN FRANCISCO, CALIF.—In a session devoted to pharmacologic approaches to reducing stent thrombosis, Dean J. Kereiakes, MD, of The Christ Hospital in Cincinnati, Ohio, focused on the advantages of the ...
This was a single-centered, open-label, parallel-design study. Subjects received a single loading dose (LD) of prasugrel followed by once-daily maintenance dose (MD) for 10 d. They were enrolled into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results